Business
Medexus to Participate in the LD Micro Invitational XIII
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 1, 2023) - Medexus Pharmaceuticals...
About this update from Medexus Pharmaceuticals Inc.
[{"type":"text","content":"Medexus to Participate in the LD Micro Invitational XIIIToronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 1, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the LD Micro Invitational XIII from June 6-8 2023.Event: LD Micro Invitational XIIIDate: June 6-8, 2023Location: Luxe Sunset Boulevard Hotel, CaliforniaMedexus Presentation: Tuesday, June 6 at 2:30 PM Pacific timeKen d'Entremont, Medexus's Chief Executive Officer, and Marcel Konrad, Medexus's Chief Financial Officer, will deliver a presentation on June 6, 2023 at 2:30 PM Pacific time and will be available for in-person one-on-one meetings throughout the conference.A livestream of the conference including the Medexus presentation is available at the following link:https://ldinv13.sequireevents.com/About MedexusMedexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. For more information about Medexus and its product portfolio, please see the company's corporate website at www.medexus.com and its filings on SEDAR at www.sedar.com.`About LD MicroLD Micro, a wholly owned subsidiary of Freedom US Markets, was founded in 2006 with the sole purpose of being an independent resource in the micro-cap space. Whether it is the Index, comprehensive data, or hosting the most significant events annually, LD's sole mission is to serve as an invaluable asset for all those interested in finding the next generation of great companies. For more information on LD Micro, visit www.ldmicro.com.ContactsKen d'Entremont | CEO, Medexus PharmaceuticalsTel: 905-676-0003 | Email: [email protected] Konrad | CFO, Medexus PharmaceuticalsTel: 312-548-3139 | Email: [email protected] Rutherford | Adelaide CapitalTel: 480-625-5772 | Email: [email protected] statementsCertain statements made in this news release contain forward-looking information within the meaning of applicable securities laws (forward-looking statements). The words \"anticipates\", \"believes\", \"expects\", \"will\", \"plans\", \"potential\", and ...